65,437 trials
Growth Hormone Deficiency
Primary: Percent rhGH Injections Missed During the Treatment Period (Based on the Easypod™ Injection Log) — 20; 19.46; 20 Percent of injections missed — p=0.908
Vision Correction
Primary: Lens Orientation — 0.77; 0.66 proportion of eyes
Healthy
Primary: Cmax of Losartan (Maximum Observed Concentration of Drug Substance in Plasma) — 637.01; 582.39 ng/mL
Ametropia
Primary: Lens Orientation Within 5 Degrees — 128; 128 Eyes
Osteoporosis · Osteopenia
Primary: Total Hip Bone Mineral Density Percent Change From Baseline at Month 12 — 2.6; 3.5 Percent Change from Baseline — p=<0.0001
Human Immunodeficiency Virus (HIV) Infections
Primary: Percentage of Participants With Treatment Failure Through Week 48 — 21.3 Percentage of Participants
Healthy
Primary: Cmax of Losartan (Maximum Observed Concentration of Drug Substance in Plasma) — 407.66; 360.82 ng/mL
Liver Transplantation · Hepatitis C, Chronic · Liver Cirrhosis
Primary: A Sustained Virologic Response (SVR), Defined as a Plasma HCV RNA Level Below the Lower Level of Quantitation (LLQ) at 24 Weeks Post-treatment — 36 Participants
Hypertension
Primary: Area Under the Curve (AUC(0 to Infinity)) of Losartan — 1018.1; 1024.9 ng*hr/mL
Refractive Error
Primary: Lens Comfort — 3.08; 3.00 units on a scale
Bipolar Disorder
Primary: Participants Who Experienced Adverse Event(s) — 23; 68; 85 Participants
Influenza
Primary: Hemagglutination Inhibition (HAI) Geometric Mean Titer (GMT) Against A/Vietnam/04 Antigen — 14.7; 27.9; 6.7; 13.6 Titer
Cardiac Arrest
Primary: Achieve Return of Spontaneous Circulation (ROSC) — 33; 43 participants
Migraine Headache
Primary: Pain Relief at 2 Hours During the First Migraine Attack Period — 246; 30; 74; 52 participants
Hepatitis B
Primary: Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentration as Measured by Enzyme-Linked Immunosorbent Assay (ELISA). — 118.6; 14.8; 142.8; 24.2 mIU/mL